<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655717</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001516</org_study_id>
    <secondary_id>R42DA043977</secondary_id>
    <nct_id>NCT03655717</nct_id>
  </id_info>
  <brief_title>Using Imaging to Assess Effects of THC on Brain Activity</brief_title>
  <acronym>fNIRS</acronym>
  <official_title>Using Imaging to Assess Effects of THC on Brain Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess effects of THC (n=150) and THC + alcohol (n =50) in MJ users on prefrontal brain
      activity with functional near infrared spectroscopy (fNIRS) during resting state and during
      memory task performance.

      To do so, 150 participants will complete fNIRS testing 120 minutes following THC or identical
      placebo at a clinically determined dose of 20-50mg dronabinol (synthetic THC) and 50
      participants will complete fNIRS testing following THC/ethanol, THC/placebo ethanol, placebo
      THC/ethanol, and placebo THC/placebo ethanol, each at at clinically determined doses designed
      to produce intoxication.

      During peak intoxication in participants determined to be intoxicated, (intoxication defined
      as self reported intoxication &gt;50 on 100 point VAS, by field sobriety testing by a Drug
      Recognition Expert, and by clinical evaluation, the fNIRS HbO signal will be significantly
      greater than at baseline and than at a post-peak assessment, and/or resting state
      connectivity will increase with THC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marijuana has become the most popular illicit drug in the western world (Substance Abuse and
      Mental Health Services Administration, 2004). Both acute and chronic exposure to cannabis is
      associated with changes in brain activity in frontal, limbic and also cerebellar regions,
      with generally increased brain activity following acute exposure and generally decreased
      activity during abstinence (Quickfall, 2006). Regions showing differences in brain activity
      involve the extended dopamine reward pathways and the frontocerebellar network.

      Most brain imaging studies of acute marijuana exposure have demonstrated global cortical
      activity increases during administration of smoked cannabis or infused THC. Several
      techniques have been used to track alterations of the brain associated with marijuana
      intoxication (Mathew and Wilson, 1992, Levin, 2001 and Mathew et al., 1997). Using positron
      emission tomography (PET), studies have shown that marijuana intoxication is associated with
      global and rCBF increases that are most notable over the frontal regions and, in right-handed
      subjects, in the right hemisphere, (Mathew et al., 1997). Ratings of intoxication and
      euphoria correlated with the right hemispheric rCBF increase (Mathew et al., 1997). In
      another PET study, Volkow et al. (1991a) showed that increased cerebellar metabolism during
      intoxication, correlated with degree of intoxication and plasma THC levels (Volkow et
      al.,1991b). FMRI studies have also shown increases in brain activity when individuals are
      intoxicated. In two pharmacological fMRI studies, Bossong and colleagues investigated the
      acute effects of THC, administered with a Volcano vaporizer (6 mg), and found that activity
      during a memory task was significantly increased in a network of memory-related brain
      regions, particularly when workload increased.

      An alternative technology to PET and fMRI that has not been used to assess the effects of THC
      on brain function is functional near-infrared spectroscopy (fNIRS). fNIRS is a neuroimaging
      technology for mapping the functioning human cortex that exploits the principles of
      near-infrared spectroscopy (NIRS). An fNIRS headset can be quickly fixed to the forehead and
      enables measurements of the prefrontal cortex (PFC) within minutes. NIRS is based on the fact
      that: 1) human tissues are relatively transparent to light in the NIR spectral window
      (650-1000 nm); 2) NIR light is either absorbed by pigmented compounds (chromophores) or
      scattered in tissues; 3) NIR light is able to penetrate human tissues (Delpy and Cope, 1997);
      and 4) the relatively high attenuation of NIR light in tissue is due to hemoglobin, the
      oxygen transport red blood cell protein, located in small vessels of the microcirculation,
      such as capillary, arteriolar and venular beds. NIRS is weakly sensitive to blood vessels &gt;1
      mm because they completely absorb the light. The absorption spectrum of hemoglobin depends on
      its level of oxygenation. NIRS is a non-invasive, safe technique that utilizes 1) laser diode
      and/or light emitting diode light sources spanning the optical window between 650 and 1000
      nm, and 2) flexible fiber optics to carry the NIR light to (source) and from (detector)
      tissues. Fiber optics are suitable for any head position and posture. Adequate depth of NIR
      light penetration (almost one half of the source-detector distance) can be achieved using a
      source-detector distance around 3 cm. fNIRS has been used in several fields in which fMRI is
      impractical due to the constraints of the fMRI scanning environment. fNIRS can be utilized,
      for example, in infant and children developmental studies, in neurorehabilitation assessment,
      and in simultaneous brain activation studies on multiple subjects. In this study, we will use
      fNIRS to assess the effects of THC intoxication on hemodynamic response and connectivity in
      the prefrontal cortex.

      Dronabinol (marinol) is an FDA approved, synthetic, orally active cannabinoid used for
      appetite stimulation that has been shown to be safe for multi dose use at doses up to 210 mg
      per day, although after dosing of 210 mg per day for 16 days, a withdrawal syndrome was
      described with abrupt discontinuation. Doses of 2.5-20 mg per day are used for appetite
      stimulation and antiemetic indications. Doses of 0.5 mg/kg body weight reliably produce
      intoxication (easy laughing, elation and subjective heightened awareness)

      II. SPECIFIC AIMS Aim 1. Assess the effects of THC intoxication using dronabinol (synthetic
      THC) on the HbO signal during resting state and task-based activation in the prefrontal
      cortex (PFC) and resting state connectivity, as well as on neurocognitive task performance
      and correlations between these measurements and clinical signs of intoxication.

      Aim 2. Investigate at which doses of dronabinol an effect on neurocognitive task performance
      or an effect on PFC activity can be observed.

      Aim 3. Examine potential interaction following co-administration of THC with oral ethanol
      exposure in healthy volunteers.

      Participants: 150 adults who use marijuana at least monthly (aged 18-55) will be recruited to
      participate in this Phase IIa study of dronabinol vs placebo. Subjects will be asked to
      refrain from using marijuana within 24 hours of the start of study procedures. Since THCCOOH,
      the main secondary metabolite of tetrahydrocannabinol (THC), can be detected in urine several
      weeks after last use, a negative urine toxicology screen for THC-COOH will not be required,
      participants will be admitted to the inpatient research unit of Massachusetts General
      Hospital the night prior to start of study procedures on each study day after screening, and
      participants who arive exhibiting overt signs of intoxication (e.g. congestion of the
      conjunctival blood vessels (red eyes), slowed speech response, giddiness) will not be tested
      the next morning.

      Study Drug and Dosing: Participants will be given up to 50 mg of dronabinol, an FDA-approved
      synthetic form of THC that is used to treat loss of appetite that causes weight loss in
      people with AIDS. THC is the principle psychoactive drug in marijuana. The study physician,
      Dr. A. Eden Evins MD, as well as physicians on study staff at the Center for Addiction
      Medicine, will be responsible for administering the drug.

      Dronabinol will be dosed to 50mg per study visit. The rationale for this dose is based on
      several factors. The study will be conducted in regular cannabis users who present at their
      first study visit with a positive urine screen for THC metabolites. Chronic cannabis use is
      associated with significant tachyphylaxis and tolerance to pharmacologic effects of THC and
      other cannabinoids. In healthy males who received 210 mg/day dronabinol for 16 days,
      tolerance developed to the CNS effects of dronabinol (including the euphoric 'high' effect)
      within 12 days. At doses of 5 mg/day for appetite stimulation in 139 patients, only 18%
      experienced ay CNS effect (feeling high, dizziness, confusion, somnolence). These CNS effects
      are the target symptoms we wish to assess in study participants. Because of tolerance, the
      rate of CNS effects is expected to be lower in our study population than in non-cannabis
      users who participated in dronabinol studies for anti-emetic and appetite stimulation
      indications.

      Dronabinol was evaluated in 454 patients with cancer at doses up to 40 mg/day. At doses
      greater than 0.175 mg/kg approximately 58% reported feeling 'high'. The starting recommended
      antiemetic dose is 15-20mg/day, noting that dosage may be escalated during a chemotherapy
      cycle or at subsequent cycles based upon initial results.

      For appetite stimulation, the recommended dose range is up to 20 mg/day, and at this dose
      approximately half of patients tested have reported CNS symptoms targeted in this study
      (feeling high, dizziness, confusion, somnolence).

      Thus, we will dose at up to 50mg and will assess for CNS symptoms frequently during the study
      visit. The exact dronabinol dose will be clinically determined by a study physician. The dose
      will be designed to minimize adverse psychologic and physiologic effects of dronabinol and
      will be primarily based on the degree of tolerance expected (based on dose and frequency of
      cannabis use), self report of degree of intoxication experienced with each use, and any
      regular or prior negative psychological reactions to cannabis use or binges. This is an
      inexact determination as potency of cannabis used is almost never known. Other factors that
      will be considered when determining dose are height, weight, BMI, and baseline blood
      pressure. For example: Heavy daily cannabis users will generally receive 50 mg. Daily
      cannabis users who use 1/2-1 gram per day and who weigh over approximately 140 pounds will
      generally receive 50 mg, while those who use less than half a gram per day, use less than
      daily or who weigh less than 120 pounds will receive between 30 and 45 mg based on the
      physician's best judgment.

      Urine Drug Screen: Before study procedures are initiated, we will perform a qualitative urine
      drug screen (Multi Drug 6 Panel Urine Test; Medimpex United Inc., Bensalem, PA) that will
      test for marijuana, amphetamines, methamphetamines, cocaine, and opiates. These rapid tests
      are simple, can be done at home, and are CLIA-waived. The test will be administered by a
      trained research coordinator.

      Urine Pregnancy: Before study procedures are initiated, we will perform a qualitative urine
      pregnancy test for females. The test will be administered by a trained research coordinator.

      Overview of Procedures Phase 2A. Investigate the effect of THC on fNIRS brain signature and
      its association with self-reported intoxication, laboratory measures of impairment, and the
      gold-standard behavioral field test of driving impairment used by law enforcement, the
      primary classifier.

      Subjects will be scheduled for 2 study sessions. In a double-blind, placebo-controlled,
      random order cross-over study of single dose THC (dronabinol) at physician determined doses
      of 20-50mg, participants will receive THC capsules or identical placebo. The MGH research
      pharmacy will generate a blinded randomization code for order of dosing and will dispense
      blinded drug in the dose ordered and identical placebo for use on separate study days. In
      order for a complete washout of effects, and to minimize the effect of repeat testing for the
      neuropsychology tasks, study visits for each subject will be conducted at least 1 week apart.
      On each study day, participants will be admitted to the MGH inpatient research unit, and will
      have a light standardized breakfast after overnight fast and sleep. They will be asked not to
      deviate from normal behaviors (e.g. if they drink caffeinated beverages or smoke cigarettes
      in the mornings, they will be asked to do so on the study day so that no symptoms of caffeine
      or nicotine withdrawal will appear during the scanning period. On each study day,
      participants will complete tests of motor function/spatial navigation and fNIRS data
      collection before study drug is administered. cognitive tasks will be repeated approximately
      90 minutes after study drug administration, fNIRS will be repeated at approximately 120
      minutes post dose, and the field sobriety test will be conducted immediately following the
      second fNIRS assessment. Blood pressure, heart rate and ratings of subjective drug effects
      will be monitored at approximately 15-minute intervals throughout the study. A third fNIRS
      assessment will be conducted when intoxication has resolved, at approximately 220 minutes
      post dose.

      Participants: 150 healthy adults, aged 18-55, who use cannabis at least weekly, will be
      enrolled. Participants must test positive for cannabis at the screening visit and have no
      serious unstable medical illness to participate (See Participant Selection Section).

      Phase 2B. Examine potential interaction following co-administration of THC with oral ethanol
      exposure in healthy volunteers.

      [Design adapted from recently published alcohol interaction studies (Modi et al., 2007;
      Trevisan et al., 2008).]

      Phase 2B is a randomized, double-blind, placebo-controlled, 2 by 2 crossover study of effect
      of dronabinol, ethanol, and combined dronabinol and ethanol on brain activation and
      connectivity as measured by fNIRS. Participants will be assigned randomly for order to
      receive single doses of each of the following study medications on 4 separate study visits
      conducted at least one week apart:

        -  Placebo THC + Ethanol

        -  THC + Placebo Ethanol

        -  THC + Ethanol

        -  Placebo THC + Placebo Ethanol

      Participants will be admitted in the evening, have an overnight fast, be provided a standard
      breakfast of approximately 400 calories (e.g. juice, cereal, bagel), approximately 45 minutes
      before administering study medication.

      Ethanol will be dosedby weight to obtain a breath alcohol concentration (BrAC) of
      approximately 0.05, consistent with BrAC following 1-2 standard drinks, using established
      methods of dosing based on previously published procedures (e.g. King 2005, Alcohol Clin Exp
      Res, Vol 29, No 4, 2005: pp 547-552).

      The required volume of 95% ethanol will be calculated from the nomogram published by Watson
      (1989), and diluted to a final concentration of 20% by volume with diet soda. The nomogram,
      based on total body water, estimated for each subject using standard equations based on
      gender, age, height, and weight (Watson et al., 1980) will be used to prepare the ethanol for
      dosing by study staff who are not otherwise involved in study procedures.

      In an attempt to standardize the drinking time to 8 minutes, the total dose will be split
      into 4 equal aliquots and placed in cups with lids. The subject will be given a cup every 2
      minutes with instructions to sip the drink using a straw.

      â€¢ Placebo Ethanol drink will be made as an equal volume of diet soda placed in identical cups
      with lids and straws. 0.25 ml of 95% ethanol will be floated on the top of the soda in each
      cup in an attempt to blind the participant and study staff who are involved with assessments
      / data acquisition.

      The alcohol administration procedure will take place approximately 45 min before the start of
      the second fNIRS session.

      Breathalyzer measurements will be taken approximately every 5-10 minutes after the alcohol
      administration procedure, until BrACs have returned to &lt;0.01. Participants will be required
      to stay in the laboratory until BrACs have returned to &lt;0.01. A member of our study staff
      will then (1) arrange cab service, and (2) escort the participant to the cab at the end of
      the study visit. Alternatively, participants may arrange travel home with a family member or
      friend. If they choose to do this, a study staff member will ensure that someone is there to
      bring them home prior to departure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">December 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a double blind, placebo controlled, 2 by 2, crossover study of the effect of intoxication with THC, ethanol, and combined THC and ethanol on brain activity as assessed with fNIRS.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects will be randomly assigned to one of the possible orders according to a randomization schedule generated by the study staff using a random number generator and computer program. The MGH research pharmacy will generate a blinded randomization code for order of dosing and will dispense blinded drug in the dose ordered and identical placebo for use on separate study days. Ethanol or placebo drink will be prepared by a member of the research unit staff not otherwise associated with study visits.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change on fNIRS (HbO) measure of prefrontal brain activity and connectivity at rest as an effect of THC intoxication</measure>
    <time_frame>effect of study medicine during 6 hour study visit</time_frame>
    <description>2 by 2 design</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on fNIRS (HbO) measure of prefrontal brain activity during memory task as an effect of THC intoxication</measure>
    <time_frame>effect of study medicine during 6 hour study visit</time_frame>
    <description>2 by 2 design</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on fNIRS (HbO) measure of prefrontal brain activity and connectivity at rest as an effect of THC + ethanol intoxication</measure>
    <time_frame>effect of study medicine during 6 hour study visit</time_frame>
    <description>2 by 2 design</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on fNIRS (HbO) measure of prefrontal brain activity during memory task ) as an effect of THC + ethanol intoxication</measure>
    <time_frame>effect of study medicine during 6 hour study visit</time_frame>
    <description>2 by 2 design</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Intoxication Alcohol</condition>
  <condition>Intoxication THC</condition>
  <condition>Intoxication Combined Alcohol THC</condition>
  <arm_group>
    <arm_group_label>Placebo Dronabinol + Ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of Placebo Dronabinol + Ethanol See protocol for dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronabinol + Placebo Ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of Dronabinol + Placebo Ethanol See protocol for dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronabinol + Ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of Dronabinol + Ethanol See protocol for dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dronabinol + Placebo Ethanol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose of Placebo Dronabinol + Placebo Ethanol See protocol for dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>THC (dronabinol) at physician determined doses of 10-50mg designed to produce intoxication.</description>
    <arm_group_label>Dronabinol + Ethanol</arm_group_label>
    <arm_group_label>Dronabinol + Placebo Ethanol</arm_group_label>
    <other_name>oral THC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).</description>
    <arm_group_label>Dronabinol + Ethanol</arm_group_label>
    <arm_group_label>Placebo Dronabinol + Ethanol</arm_group_label>
    <other_name>oral ethanol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Dronabinol</intervention_name>
    <description>Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)</description>
    <arm_group_label>Placebo Dronabinol + Ethanol</arm_group_label>
    <arm_group_label>Placebo Dronabinol + Placebo Ethanol</arm_group_label>
    <other_name>placebo THC capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ethanol</intervention_name>
    <description>Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.</description>
    <arm_group_label>Dronabinol + Placebo Ethanol</arm_group_label>
    <arm_group_label>Placebo Dronabinol + Placebo Ethanol</arm_group_label>
    <other_name>oral placebo ethanol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weekly or greater Marijuana users

          -  Aged 21-55

          -  Participants must test positive for cannabis and have no serious unstable medical
             illness

        Exclusion Criteria:

          -  Any unstable, serious medical illness, eg. unstable angina, or cardiovascular event in
             the past 6 months eg. myocardial infarction or stroke.

          -  Diabetes, seizure disorder, cirrhosis, schizophrenia, bipolar disorder, clinically
             significant cardiac conduction disorder, uncontrolled hypertension, tachycardia, renal
             failure;

          -  History of syncope, HIV, Hepatitis C, migraines, head injury with prolonged
             unconsciousness (&gt; 24 hours);

          -  Allergy to sesame oil (contained in Marinol pills) or marinol capsules

          -  Current regular use of benzodiazepines or barbiturates, antihistamines, atropine,
             scopolamine, other anticholinergic agents;

          -  Current pregnancy or lactation, or trying to become pregnant (confirmed by urine
             pregnancy test)

          -  Currently seeking treatment, in treatment, or in recovery from an alcohol use
             disorder.

          -  In the opinion of the investigator, not able to safely participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Eden Evins, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jodi M Gilman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jodi M Gilman, PhD</last_name>
    <phone>617-643-4679</phone>
    <email>jgilman1@MGH.HARVARD.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Maravic, PHD</last_name>
    <phone>617-643-1771</phone>
    <email>MMARAVIC@MGH.HARVARD.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Addiction Medicine, Massachusetts General Hospital, Dept. of Psychiatry</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa C Maravic, PhD, MPH</last_name>
      <phone>617-643-1771</phone>
      <email>melissa.maravic@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>A Eden Evins, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jodi Gilman, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>A. Eden Evins</investigator_full_name>
    <investigator_title>Director, Center for Addiction Medicine</investigator_title>
  </responsible_party>
  <keyword>fNIRS</keyword>
  <keyword>THC</keyword>
  <keyword>Intoxication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholic Intoxication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

